| ［1］ |
Bhardwaj P, Basu D, Podder I, et al. Clinico⁃epidemiological profile of childhood alopecia areata along with dermoscopic correlation: a cross⁃section, observational study［J/OL］. Indian Dermatol Online J, 2021,12（2）:250⁃257. doi: 10.4103/idoj.IDOJ_451_20.
|
| ［2］ |
Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2020,82（3）:675⁃682. doi: 10.1016/j.jaad.2019.08.032.
|
| ［3］ |
Peloquin L, Castelo⁃Soccio L. Alopecia areata: an update on treatment options for children［J］. Paediatr Drugs, 2017,19（5）:411⁃422. doi: 10.1007/s40272⁃017⁃0239⁃z.
|
| ［4］ |
Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（4）:1164⁃1166. doi: 10.1016/j.jaad.2018.12.041.
|
| ［5］ |
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children［J］. J Am Acad Dermatol, 2019,80（2）:568⁃570. doi: 10.1016/j.jaad.2018.08.041.
|
| ［6］ |
Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre⁃adolescent children with oral tofacitinib: a retrospective study［J］. Pediatr Dermatol, 2021,38（1）:103⁃108. doi: 10.1111/pde.14422.
|
| ［7］ |
Huang J, Li T, Tan Z, et al. Effectiveness of tofacitinib in pre⁃adolescent alopecia areata: a retrospective case series and literature review［J］. Acta Derm Venereol, 2023,103:adv13418. doi: 10.2340/actadv.v103.13418.
|
| ［8］ |
刘元香, 梁源, 赵欣荣, 等. JAK抑制剂治疗儿童重症斑秃5例［J］. 中华皮肤科杂志, 2023,56（9）:849⁃852. doi: 10.35541/cjd. 20220317.
|
| ［9］ |
Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: a 6⁃year⁃old child's case report［J］. Int J Trichology, 2021,13（6）:32⁃33. doi: 10.4103/ijt.ijt_91_21.
|
| ［10］ |
Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis［J］. JAMA Dermatol, 2021,157（3）:352⁃353. doi: 10.1001/jamadermatol.2020.4555.
|
| ［11］ |
Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate⁃to⁃severe alopecia areata in pre⁃adolescent children with baricitinib［J］. Br J Dermatol, 2023,189（2）:248⁃250. doi: 10.1093/bjd/ljad118.
|
| ［12］ |
Rotaru S, Common M, Mahé E. Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata［J］. Ann Dermatol Venereol, 2023,150（2）:160⁃161. doi: 10.1016/j.annder.2023.02.001.
|
| ［13］ |
Fiocco Z, Kerl K, French LE, et al. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis［J］. Dermatol Ther, 2022,35（4）:e15351. doi: 10.1111/dth.15351.
|
| ［14］ |
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（2）:566⁃568. doi: 10.1016/j.jaad.2018.08.040.
|
| ［15］ |
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:850⁃856. doi: 10.1111/jdv.15489.
|
| ［16］ |
Ali NS, Tollefson MM, Lohse CM, et al. Incidence and comorbidities of pediatric alopecia areata: a retrospective matched cohort study using the Rochester Epidemiology Project［J］. J Am Acad Dermatol, 2022,87（2）:427⁃429. doi: 10.1016/j.jaad.2021.08.050.
|
| ［17］ |
Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221138452. doi: 10.1177/2050313X221138452.
|
| ［18］ |
Yu D, Ren Y. Upadacitinib for successful treatment of alopecia universalis in a child: a case report and literature review［J］. Acta Derm Venereol, 2023,103:adv5578. doi: 10.2340/actadv.v103.5578.
|
| ［19］ |
King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double⁃blind, multicentre, phase 2b⁃3 trial［J］. Lancet, 2023,401（10387）:1518⁃1529. doi: 10.1016/S0140⁃6736（23）00222⁃2.
|
| ［20］ |
Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib［J］. JAAD Case Rep, 2022,22:99⁃100. doi: 10.1016/j.jdcr.2022.02.027.
|
| ［21］ |
Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib［J］. J Cosmet Dermatol, 2024,23（1）:348⁃349. doi: 10.1111/jocd.15896.
|
| ［22］ |
Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.
|
| ［23］ |
Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo⁃controlled single⁃center pilot study of the safety and efficacy of apremilast in subjects with moderate⁃to⁃severe alopecia areata［J］. Arch Dermatol Res, 2019,311（1）:29⁃36. doi: 10.1007/s00403⁃018⁃1876⁃y.
|
| ［24］ |
Chhabra G, Verma P. Steroid⁃resistant alopecia totalis in a child successfully treated with oral apremilast and platelet⁃rich plasma therapy［J］. Dermatol Ther, 2019,32（6）:e13082. doi: 10.1111/dth.13082.
|
| ［25］ |
Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a janus effect［J］. Dermatol Ther, 2019,32（5）:e13023. doi: 10.1111/dth.13023.
|
| ［26］ |
Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata［J］. J Am Acad Dermatol, 2023,88（3）:651⁃653. doi: 10.1016/j.jaad.2019.06.010.
|
| ［27］ |
Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis［J］. JAAD Case Rep, 2021,16:82⁃85. doi: 10.1016/j.jdcr.2021.07.015.
|
| ［28］ |
McKenzie PL, Castelo⁃Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis［J］. J Am Acad Dermatol, 2021,84（6）:1691⁃1694. doi: 10.1016/j.jaad.2021.01.046.
|
| ［29］ |
Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata［J］. Pediatr Dermatol, 2019,36（1）:e44⁃e45. doi: 10.1111/pde.13699.
|
| ［30］ |
Ortolan LS, Kim SR, Crotts S, et al. IL⁃12/IL⁃23 neutralization is ineffective for alopecia areata in mice and humans［J］. J Allergy Clin Immunol, 2019,144（6）:1731⁃1734.e1. doi: 10.1016/j.jaci. 2019.08.014.
|
